IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10744128 B1

PDFFull Text
Date of Patent:
Aug. 18, 2020

Filed:

Jul. 31, 2019

6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof

Applicant:

Samumed, Llc, San Diego, CA (US);

Inventors:

Sunil Kumar KC, San Diego, CA (US);

Chi Ching Mak, San Diego, CA (US);

Brian Walter Eastman, San Diego, CA (US);

Jianguo Cao, San Diego, CA (US);

Gopi Kumar Mittapalli, San Diego, CA (US);

Assignee:

Samumed, LLC, San Diego, CA (US);

Attorney:

Fish & Richardson P.C.

Primary Examiner:

Timothy R Rozof

Int. Cl.
CPC ...
C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); A61K 31/4725 (2006.01); A61P 7/00 (2006.01); A61P 19/02 (2006.01); A61P 25/28 (2006.01); A61P 3/00 (2006.01); A61P 11/00 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 25/00 (2006.01); A61P 25/16 (2006.01); A61P 19/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4725 (2013.01); A61P 3/00 (2018.01); A61P 7/00 (2018.01); A61P 11/00 (2018.01); A61P 19/00 (2018.01); A61P 19/02 (2018.01); A61P 25/00 (2018.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01);
Abstract

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Find Patent Forward Citations

Loading…